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 Abstract 
 
The aim of this study was to determine whether the downregulation of endogenous Fes 
by siRNA in cultured endothelial cells affects vascular endothelial growth factor-A 
(VEGF-A)-induced chemotaxis and capillary-like morphogenesis, which are 
considered as angiogenic cellular responses in vitro. VEGF-A-treatment induced 
autophosphorylation of Fes in cultured endothelial cells. LY294002, a phosphoinositide 
3-kinase inhibitor, significantly inhibited VEGF-A-induced chemotaxis and 
capillary-like morphogenesis. Downregulation of Fes attenuated these 
VEGF-A-induced cellular responses but LY294002 did not produce further inhibition 
of these responses. Downregulation of Fes neither affected VEGF-A-induced 
autophosphorylation of VEGF receptor 2 nor mitogen-activated protein kinase 
activation, but markedly decreased Akt activation. Taken together, our novel results 
indicate the involvement of Fes in VEGF-A-induced cellular responses by cultured 
endothelial cells. 
 
Key words: VEGF-A, Fes, siRNA, endothelial cell, chemotaxis, capillary-like 
morphogenesis 
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Introduction 
 
Non-receptor protein tyrosine kinase Fes, distinct from c-Src, c-Abl, and other 
non-receptor protein tyrosine kinases [1, 2], is exclusively expressed in hematopoietic 
and vascular endothelial cells [3]. Fes is activated by oligomerization and subsequent 
autophosphorylation [4, 5]. Expression of kinase-inactive Fes (KI-Fes) in cultured 
endothelial cells exerts dominant negative effect on endogenous Fes [6]. Using stable 
cell lines expressing KI-Fes, we demonstrated previously the involvement of Fes in 
chemotaxis of murine brain capillary endothelial cells (IBE cells) induced by fibroblast 
growth factor-2 (FGF-2) and angiopoietin 2 (Ang 2) [6, 7], and tube formation or 
capillary-like morphogenesis (i.e. morphological differentiation) induced by stromal 
cell-derived factor 1- (SDF-1) and sonic hedgehog (Shh) [8, 9]. Ang2-, SDF-1- and 
Shh-induced activation of phosphoinositide-3 -kinase (PI3-kinase) is dependent on 
c-Fes kinase activity, whereas FGF-2 activates Src within focal adhesions in a manner 
dependent on Fes activity [10]. These results suggest that Fes could be a potential target 
for antiangiogenic therapy designed to shutdown intracellular signals mediated by 
multiple proangiogenic factors simultaneously. 
Vascular endothelial growth factor (VEGF) is a family of closely related 
polypeptides, comprising VEGF-A, -B, -C, -D, -E, and placental growth factor [11, 12]. 
Their specific receptor tyrosine kinases are VEGF receptor (VEGFR)-1, -2, and -3 [13]. 
We have previously shown that a prototype VEGF, VEGF-A, activated Fes through 
VEGFR-2, but not through VEGFR-1, in porcine aortic endothelial cells [14]. In these 
cells, Fes contributed to VEGF-A-promoted activation of PI3-kinase. However, 
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expression of KI-Fes failed to exhibit dominant negative effect on VEGF-A-activated 
PI3-kinase because other signaling molecules, such as VEGFR-2, Src, and 
insulin-receptor substrate I, seemed to compensate the loss of Fes kinase activity [14]. 
Accordingly, chemotaxis and capillary-like morphogenesis by VEGF-A-treatment 
were not inhibited by the expression of KI-Fes [14]. These results suggest that 
inhibition of endogenous Fes activity may not sufficiently suppress VEGF-A-driven 
angiogenesis. Since VEGF-A plays central roles in tumor angiogenesis [15], it is 
important to know whether targeting Fes is a suitable strategy for antiangiogenic tumor 
therapy. Fes has a unique amino-terminal domain containing two coiled-coil domains 
and a Src-homology 2 (SH2) domain, it is plausible that these domains provide a 
scaffold function to transduce signals in the absence of Fes tyrosine kinase activity. To 
address this issue, we examined the effect of the downregulation of Fes protein using 
small interfering RNA (siRNA) on VEGF-A-promoted cellular responses by 
endothelial cells.
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Materials and methods 
 
Materials  
Recombinant human VEGF-A (165 amino acids) was obtained from PeproTech 
(London, UK). Type I collagen gel was purchased from Cohesion Technologies Inc. 
(Palo Alto, CA). Growth factor-reduced Matrigel® matrix was purchased from BD 
Bioscience (Bedford, MA). Anti-Fes antibody (N-16), anti-VEGFR-2 antibody, 
anti-Akt monoclonal antibody, anti-ERK1 antibody, and anti-phosphotyrosine antibody 
(PY99) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 
Anti-phospho-mitogen-activated protein kinase (MAPK) polyclonal antibody and 
anti-phospho Akt 1 (pS473) were obtained from Cell Signaling Technology, Inc., 
(Beverly, MA). HiPerFect® transfect reagent, negative control siRNA, and human Fes 
siRNA (Hs_FES_6_HP Validated siRNA) were purchased from Qiagen (Tokyo, Japan). 
The PI3-kinase inhibitor LY294002 was obtained from Merck Company (Tokyo). 
LY294002 was dissolved in dimethyl sulfoxide (DMSO) and the final concentration of 
DMSO in the culture medium was always 0.1% (Vo/Vo). As a vehicle, 0.1% DMSO 
was added to the cells without treatment with LY294002. 
 
Cell culture  
Human umbilical vein endothelial cells (HUVECs) and their culture medium were 
obtained from Cambrex (Walkersville, MD). The cells were cultured in endothelial cell 
basal medium-2 (EBM-2) supplemented with 2% fetal bovine serum, 10 ng/ml 
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VEGF-A, 20 ng/ml FGF-2, 10 ng/ml endothelial growth factor, 10 ng/ml insulin-like 
growth factor-I, 50 g/ml ascorbic acid, 100 ng/ml heparin, and 10 pM dexamethasone. 
 
Preparation of siRNA-treated HUVECs  
HUVECs were transfected with siRNA using HiPerFect reagent as described 
previously [16]. In brief, either negative control or Fes siRNA was transfected into 
HUVECs. After 2 or 3 days, the cells were used for the chemotaxis assay or the 
capillary morphogenesis assay. Alternatively, the cells were serum- and growth 
factor-starved for 2 h and then either stimulated or unstimulated with VEGF-A, lysed, 
and used for immunoblotting. 
 
Chemotaxis assay  
Chemotaxis assay was performed as described previously [17]. Briefly, the membranes 
of Transwell membrane filters (Corning Coster Japan, Tokyo) were coated with type I 
collagen gels. Cells suspended in EBM-2 containing 0.5% FBS were seeded onto the 
upper well of Transwell inserts, and test samples were added to the medium in the lower 
well. Four hours later, cells that migrated onto the lower surface of the membranes were 
counted under microscopy.  
 
Capillary-like morphogenesis assay  
HUVECs suspended in EBM-2 medium containing 0.5% FBS with or without the 
indicated treatments were seeded onto growth factor-reduced Matrigel and cultured for 
up to 24 h [9]. To quantify the length of capillary-like structures, three different 
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phase-contrast photomicrographs (x 4 objectives) per well were taken, and the length of 
each capillary-like structure was measured using NIH image software (version 1.64). 
The length of capillary-like structures of control siRNA-treated HUVECs cultured in 
the presence of 100 ng/ml of VEGF-A was set to 1.0. 
 
Immunoprecipitation and immunoblotting 
Immunoprecipitation and immunoblotting were performed as described previously [16]. 
The indicated proteins were immunoprecipitated with specific antibodies and separated 
onto SDS-PAGE. For examination of loaded protein for Fes downregulation, 10% of 
the total cell lysate was separated onto SDS-PAGE. To detect activation of 
mitogen-activated protein kinase (MAPK), total cell extracts prepared by the direct 
addition of boiled SDS-sample buffer to the cells were used. After transfer of the 
proteins onto polyvinylidene difluoride membranes, the blots were probed with the 
indicated primary antibodies followed by detection through enhanced 
chemiluminescence reaction and exposure to X-ray film. Stripping was conducted 
between the two probings.  
 
Statistical analysis  
Values are presented as mean capillary length ± SD. Differences between two groups 
were determined by Mann-Whitney’s U test. Differences were considered significant 
when the P value was less than 0.05. 
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Results 
 
Downregulation of Fes protein attenuates VEGF-A-induced chemotaxis and 
capillary-like morphogenesis by HUVECs  
We first examined whether VEGF-A activates endogenous Fes in HUVECs. As shown 
in Fig. 1A, VEGF-A-treatment induced autophosphorylation of Fes in HUVECs, 
suggesting that Fes acts as a signaling molecule in VEGF-A-treated HUVECs. We then 
examined the effect of Fes siRNA on Fes protein expression in HUVECs. As shown in 
Fig. 1B, treatment of HUVECs with Fes siRNA downregulated the expression of Fes 
protein by up to 78%.  
Next, we examined the effect of downregulation of Fes protein on chemotaxis 
and capillary-like morphogenesis by HUVECs. As shown in Fig. 2, PI3-kinase inhibitor 
LY294002 significantly inhibited the chemotaxis of control siRNA-treated HUVECs 
toward VEGF-A. In cells treated with Fes siRNA, chemotaxis toward VEGF-A was 
attenuated. Treatment with VEGF-A did not significantly increase the process and such 
cells showed a similar degree of chemotaxis even in the presence of LY294002, 
suggesting that downregulation of Fes may effect VEGF-A-induced activation of 
PI3-kinase. VEGF-A-treated capillary-like morphogenesis was also impaired by 
treatment of HUVECs with Fes siRNA (Fig. 3). LY294002 inhibited VEGF-A-induced 
capillary-like morphogenesis by HUVECs treated with control siRNA, but not with Fes 
siRNA. Another human Fes siRNA (Hs_FES_5_HP Validated siRNA from Qiagen) 
also downregulated Fes in HUVECs and similar effects on VEGF-A-induced 
chemotaxis and capillary-like morphogenesis were observed (data not shown). 
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Downregulation of Fes affects VEGF-A-mediated activation of Akt  
We first examined whether treatment with Fes siRNA attenuates VEGF-A-induced 
activation of VEGFR-2. As shown in Fig. 4A, treatment with Fes siRNA did not 
decrease the autophosphorylation of VEGFR-2. We also examined VEGF-A-induced 
MAPK activation. In both control siRNA- and Fes siRNA-treated cells, VEGF-A 
treatment produced comparable activation of MAPK. Since Akt is an important 
downstream effecter of PI3-kinase, we then examined the effect of Fes downregulation 
on VEGF-A-induced activation of Akt and found that Akt activation was impaired in 
Fes siRNA-treated cells. This observation suggests that downregulation of Fes seems to 
affect VEGF-A-induced activation of PI3-kinase/Akt pathway. 
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Discussion 
 
In the present study, we showed for the first time that downregulation of Fes in cultured 
endothelial cells attenuated VEGF-A-induced Akt activation with subsequent inhibition 
of chemotaxis and capillary-like morphogenesis. These findings suggest that 
downregulation of Fes protein nay potentially inhibit VEGF-A-dependent tumor 
angiogenesis.  
            Treatment with Fes siRNA downregulated the expression of Fes protein in 
HUVECs (Fig. 1 B). VEGF-A-induced chemotaxis and capillary-like morphogenesis 
by negative control siRNA-treated HUVECs were significantly inhibited by the 
treatment with LY294002. However, LY294002-treatment failed to inhibit 
VEGF-A-induced chemotaxis and capillary-like morphogenesis by Fes siRNA-treated 
HUVECs. These results suggest that VEGF-A-induced chemotaxis and capillary-like 
morphogenesis is at least partly regulated through PI3-kinase and Fes may be involved 
in the activation of this kinase. Indeed, downregulation of Fes neither inhibited 
VEGF-A-promoted autophosphorylation of VEGFR-2 nor activation of MAPK, but 
attenuated Akt phosphorylation. Thus, Fes plays significant roles in VEGF-A-promoted 
activation of PI3-kinase/Akt pathway and subsequent particular cellular responses, such 
as chemotaxis and capillary-like morphogenesis. 
Tumor angiogenesis is not solely regulated by VEGF-A. In a preclinical model, 
chronic inhibition of VEGF-A signaling altered the characteristics of tumor growth 
from VEGF-A-dependent angiogenesis to FGF-2-dependent angiogenesis [18]. Hence, 
it would be clinically valuable to block the intracellular signaling molecules that 
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commonly act downstream of a panel of proangiogenic factor receptors, because this 
strategy may shutdown the signals via multiple receptors simultaneously. Fes is 
involved in FGF-2- and Ang2-induced chemotaxis, and SDF-1- and Shh-induced 
morphological differentiation [6-10]. These data were obtained by the use of stable 
endothelial cell lines expressing KI-Fes, which exerts a dominant negative effect on 
endogenous Fes. Therefore, inhibition of Fes tyrosine kinase activity could be a 
potentially useful strategy against angiogenesis in cancer therapy. This inhibition may 
also be achieved by the use of small-molecular-weight synthetic protein kinase 
inhibitors, such as Gleevec. However, our previous study showed that expression of 
KI-Fes failed to exert dominant negative effect on VEGF-A-induced chemotaxis and 
capillary-like morphogenesis [14]. This might be due to the compensatory mechanisms 
underlying multiple pathways other than Fes, such as Src and VEGFR-2 [14], to 
activate the PI3-kinase/Akt pathway driven by VEGF-A. PI3-kinase/Akt pathway 
regulates survival, motility, and nitric oxide synthesis by endothelial cells [19]. Since 
Fes has several domains involved in the intermolecular association, such as SH2 
domain, these domains could function as a scaffold to activate PI3-kinase independent 
of Fes kinase activity. SH2 domain of Fes binds to an autophosphorylation site in Fes, 
Y713 [20]. When Fes kinase is not activated or kinase activity is inhibited, its SH2 
domain cannot associate with the autophosphorylation site. Unbound SH2 domain can 
bind to an adopter protein, Cas [21], and Cas binds to focal adhesion kinase [22], which 
could be associated with PI3-kinase [23]. Therefore, SH2 domain of Fes may be 
involved in the activation of PI3-kinase independent of Fes activity. Also, Fes has a 
consensus SH2 binding motif for the p85 subunit of PI3-kinase (pYXXM) [1]. This 
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motif includes Y633, which is not identified as an autophosphorylation site. It is 
however plausible that this tyrosine residue may be phosphorylated by other tyrosine 
kinases, which in turn creates a binding site for PI3-kinase. Because activation of class I 
PI3-kinases involves the binding to tyrosine phosphorylated proteins [24], these events 
may activate PI3-kinase independent of Fes kinase activity (Fig. 5). 
VEGF-A is a major proangiogenic factor in a variety of angiogenesis-dependent 
diseases. Thus, inhibition of VEGF-A-mediated signaling must be included in any 
antiangiogenic strategy. In the present study, we downregulated the expression of Fes 
protein in endothelial cells. Consequently, VEGF-A-induced chemotaxis and 
capillary-like morphogenesis were inhibited through impaired activation of Akt, 
suggesting that this strategy may affect the compensatory mechanism responsible for 
the activation of PI3-kinase by VEGF-A. Because small-molecular-weight kinase 
inhibitors that inhibit Fes activity are not available at present, downregulation of Fes in 
tumor tissue would be a favorable option in any novel antiangiogenic strategy. 
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Figure legends 
 
Fig. 1.  (A). VEGF-A induces autophosphorylation of Fes in HUVECs. HUVECs 
grown in 15-cm dishes were serum- and growth factor-starved for 2 h. Orthovanadate at 
100 M was added to the cells and 10 min later, the cells were either stimulated or left 
unstimulated with 200 ng/ml of VEGF-A for 15 min. Cells were washed, lysed, and Fes 
was immunoprecipitated. Autophosphorylation of Fes was examined by 
immunoblotting. (B). Downregulation of Fes by siRNA. HUVECs grown in 10 cm 
dishes were transfected with either control siRNA or Fes siRNA at 20 nM and three 
days later, Fes was immunoprecipitated from 95% of lysate, separated by SDS-PAGE, 
and Fes protein was visualized by immunoblotting. The remaining 5% of lysate was 
examined for -actin expression by immunoblotting as a loading control. Similar 
results were obtained in two independent experiments.  
 
Fig. 2. Treatment of HUVECs by Fes siRNA inhibits chemotaxis toward VEGF-A. 
Culture media containing VEGF-A at indicated concentrations, with or without 5 M 
LY294002, were placed in the lower wells of Transwell culture plates. HUVECs were 
pretreated with either 20 nM control siRNA or Fes siRNA for 66 h, suspended in 
EBM-2 supplemented with 0.5% FBS with or without LY294002 at 5 M, and seeded 
into the upper wells. The number of HUVECs that migrated onto the lower surface of 
Transwell inserts was counted. Data are mean numbers ± SD for quadruplicate wells. 
The results were reproduced in two independent experiments. 
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Fig. 3. Treatment of HUVECs by Fes siRNA inhibits VEGF-A-induced capillary 
morphogenesis. HUVECs pretreated with either 20 nM control siRNA or Fes siRNA 
for 40 h were cultured on the surface of growth factor-reduced Matrigel in the presence 
or absence of VEGF-A at indicated concentrations with or without 5 M LY294002 for 
24 h. Photographs were taken under a phase-contrast microscope. Capillary length of 
control siRNA-treated cells cultured in the presence of 100 ng/ml of VEGF-A was set to 
1.0. Values are expressed as mean ± SD of three images. Bar, 50 m. Reproducible 
results were obtained from two independent experiments. 
 
Fig. 4. (A). Treatment of HUVECs by Fes siRNA does not affect VEGF-A-induced 
autophosphorylation of VEGFR-2. HUVECs treated with either control siRNA or Fes 
siRNA at 20 nM for 66 h were serum-starved for 2 h and either stimulated or left 
unstimulated with 200 ng/ml of VEGF-A for 10 min. Autophosphorylation of 
VEGFR-2 was examined by immunoprecipitation, followed by immunoblotting. (B). 
Treatment of HUVECs by Fes siRNA does not affect VEGF-A-induced activation of 
MAPK. HUVECs treated with either control siRNA or Fes siRNA were serum-starved 
for 2 h and either stimulated or left unstimulated with 200 ng/ml of VEGF-A for 10 min. 
Activated MAPK was detected by immunoblotting. (C). Treatment of HUVECs by Fes 
siRNA attenuates VEGF-A-induced activation of Akt. HUVECs treated with either 
control siRNA or Fes siRNA were serum-starved for 2 h and either stimulated or left 
unstimulated with 200 ng/ml of VEGF-A for 10 min. Activated Akt was detected by 
immunoprecipitation, followed by immunoblotting. Reproducible results were obtained 
from two independent experiments. 
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Fig. 5. Possible mechanisms involved in VEGF-A-induced activation of PI3-kinase 
through Fes protein. VEGF-A activates Fes through VEGFR-2 [14]. Activated Fes form 
oligomer and PI3-kinase activity is co-precipitated with Fes, suggesting that the portion 
of activated PI3-kinase binds to oligomerized Fes. Alternatively, unknown kinase X 
mat phosphorylate inactive monomeric Fes on tyrosine residue to create a binding site 
for p85 subunit of PI3-kinase or yet unknown adapter protein Y. PI3-kinase may bind to 
phosphorylated monomeric Fes or phosphorylated adapter protein Y and activated. 
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